The Second Bite of the Apple: How Selling Shareholders Capture Additional Value in an ESOP

Quick answer

Most owners assume selling is the end of the story. You take your check, you hand over the keys, and whatever the company becomes next belongs to somebody else. An ESOP doesn't have to work that way.

The "second bite of the apple" is the additional value selling shareholders can earn after the sale has already closed. It usually comes in the form of warrants, a type of synthetic equity granted at closing, which lets sellers share in the company's growth as it pays down its transaction debt and builds value over the years that follow. It isn't guaranteed and it isn't free. But it often becomes a substantial piece of what an owner ultimately takes away, and it's one of the things that makes an ESOP genuinely different from every other exit on the table. It’s also one of the reasons why selling to an ESOP can generate more wealth (over time) than an offer from a typical financial buyer.

Why sellers get a second bite at all

Let’s start with a piece of the transaction that surprises a lot of owners the first time they hear it: in most ESOP deals, the seller helps finance the sale.

In other words, senior lenders will fund part of the purchase price, but rarely all of it. The gap gets filled with seller notes, meaning the selling shareholders accept a promise of future payment for a portion of what they're owed. Those notes sit behind the bank in line. If the company hits a rough patch, the bank gets paid first, and the seller waits.

That's real risk, and it's the reason synthetic equity exists in these transactions. The warrants compensate the seller for taking a subordinated position and for accepting payment over time rather than all at closing.



What a warrant actually is

A warrant is a right to buy stock at a set price, at some point in the future. Nothing more complicated than that.

Say the warrant lets the holder buy shares at a fixed price per share. If the company's value climbs above that price over the following years, the warrant is worth the difference. If the value never gets there, the warrant expires worth nothing.

Warrants are one form of what the industry calls synthetic equity. Stock appreciation rights and phantom stock work on similar logic, tracking company value without transferring actual shares at the outset. Which instrument fits depends on the structure, the tax picture, and what the parties negotiate.

The important thing for an owner to understand is that these instruments track value. They aren't a fixed payment, and they aren't a promise. They're a stake in what happens next.

How the value builds after closing

Here's the mechanic that makes synthetic equity worth paying attention to.

At closing, the company takes on debt to fund the purchase of its own stock. That leverage depresses the equity value considerably. The business is the same business it was the week before, but the balance sheet now carries an obligation, and equity is what's left after the debt.

Then the company starts paying that debt down. Every year of principal reduction moves value back to the equity, even if the business simply performs the way it always has. Add actual growth on top of that, and the equity value can climb substantially over the years following the transaction.

Warrants struck near that lower, post-closing value are positioned to capture the recovery and the growth together. That's the whole idea, and it's why the second bite can end up being a larger number than owners expect when they first see the term sheet.

What determines whether it amounts to much

Several things, and they're important to understand before the negotiation rather than after:

• Company performance is the obvious one. Synthetic equity rewards growth, and it punishes decline. Owners who stay involved in some capacity, or who've built a leadership team capable of running things well, tend to see better outcomes.
• The pace of debt paydown matters just as much. Strong free cash flow accelerates the equity recovery. Heavy capital requirements or working capital swings slow it down.
• Then there are the terms themselves: the strike price, how many warrants are issued relative to the company's equity, how long they run, and how they eventually get settled. These are negotiated with the trustee, and they're where experienced representation earns its keep.

One honest caveat on the economics. The trustee evaluates the entire package, and synthetic equity is part of the price the company is paying. A generous warrant position affects what the trustee can justify paying in cash and notes. What matters is the total consideration, not any single component of it, and modeling the whole picture is the only way to compare structures sensibly.

Tax treatment also varies by instrument and by how the transaction is structured, which is another reason to model this specifically rather than assume.

Why this isn't the same as selling more stock later

It’s worth clearing up, because the two are easily conflated.

Some owners sell only a portion of their shares in the initial transaction and sell another block years afterward, once the original debt has been retired and the company can support new financing. That's a phase two transaction. It's a separate sale of actual stock, negotiated at that time, at whatever the company is worth then.

Synthetic equity is different. It's part of the original transaction, agreed to at closing, and it pays based on appreciation rather than on selling anything further. An owner might have both. Plenty do. But they're distinct mechanisms, and mixing up the terms leads to confused expectations about when money actually arrives.

The bottom line

The second bite of the apple is one of the least understood parts of an ESOP transaction and one of the most consequential. Owners who evaluate an offer only on the cash at closing are looking at part of the picture.

If you're weighing what a transaction might actually deliver over time, we're happy to walk through how the pieces fit together in your situation.

Frequently asked questions

Q. Is the second bite of the apple guaranteed?

No. Synthetic equity pays based on future company value. If the business underperforms, the instruments can be worth little or nothing. It's genuine upside participation, with the risk that comes with it.

Q. Does synthetic equity take value away from employees?

It does affect the value that accrues to the ESOP, which is exactly why the trustee negotiates it. The trustee's job is to ensure the trust isn't overpaying once every component of the deal is accounted for. Synthetic equity is evaluated as part of that total.

Q. How is this different from private equity rollover equity?

With a financial buyer, rollover means keeping actual ownership in the new entity and waiting for that buyer to sell again, on their timeline. Synthetic equity in an ESOP pays based on the company's own performance, without depending on another sale to a third party.

Q. Do selling shareholders pay anything for the warrants?

Not out of pocket at closing, though they're not free either. They're negotiated consideration for accepting seller notes and subordinated risk, and they factor into the overall economics the trustee approves.

Q. When does the money actually arrive?

It depends on the terms. Warrants typically have a defined exercise window and a settlement mechanism agreed at closing, often years out, once the transaction debt is substantially repaid.